{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:06Z","timestamp":1790720346127,"version":"4.1.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mogamulizumab is being increasingly prescribed for the treatment of T-cell lymphomas (MF\/SS\/ATLL). We conducted a retrospective cohort study to identify muscular immune-related adverse events (irAEs) associated with mogamulizumab in patients with T-cell lymphoma followed at Dana-Farber Cancer Institute from January 2015 to June 2022. We identified 5 cases of mogamulizumab-associated myositis and\/or myocarditis (MAM\/Mc), 2 additionally affected by myasthenia gravis, among 42 patients with T-cell lymphoma. Three cases experienced \u00admogamulizumab-associated rash (MAR) prior to developing MAM\/Mc. The incidence (n = 5\/42, 11.9%) of muscular mogamulizumab-associated irAEs may be higher than has been previously reported in clinical trials and may be of late onset (a median of 5 cycles and as late as 100 days from the last infusion). We highlight the utility of IVIG, together with systemic corticosteroids, for the treatment of these potentially fatal side effects associated with mogamulizumab therapy.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad155","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:23:32Z","timestamp":1686183812000},"page":"e694-e698","source":"Crossref","is-referenced-by-count":9,"title":["Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and\/or Myocarditis in Patients With T-Cell Lymphoma"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-7360","authenticated-orcid":false,"given":"Cesar A","family":"Virgen","sequence":"first","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital , Boston, MA , USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A","family":"Sparks","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meabh J","family":"O\u2019Hare","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-8242","authenticated-orcid":false,"given":"Amrita","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Minnesota , Minneapolis, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0357-6916","authenticated-orcid":false,"given":"Jordan T","family":"Said","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6548-9746","authenticated-orcid":false,"given":"Marianne","family":"Tawa","sequence":"additional","affiliation":[{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-834X","authenticated-orcid":false,"given":"Nicole R","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital , Boston, MA , USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-2916","authenticated-orcid":false,"given":"Thomas S","family":"Kupper","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital , Boston, MA , USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-8584","authenticated-orcid":false,"given":"David C","family":"Fisher","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Larocca","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital , Boston, MA , USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"9","key":"2023080322073525000_CIT0001","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14740338.2019.1643837","article-title":"A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-cell lymphoma","volume":"18","author":"Afifi","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"2023080322073525000_CIT0002","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"2023080322073525000_CIT0003","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-19-2742","article-title":"Mogamulizumab forecast: Clearer patients, with a slight chance of immune Mayhem","volume":"25","author":"Larocca","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2023080322073525000_CIT0004","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"2023080322073525000_CIT0005","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and Sezary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023080322073525000_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"5","key":"2023080322073525000_CIT0007","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"2","key":"2023080322073525000_CIT0008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with Sezary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023080322073525000_CIT0009","article-title":"Immune-related adverse events from mogamulizumab in cutaneous T-cell lymphoma: a \u00adsingle-center experience","author":"Jfri"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e694\/51034786\/oyad155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e694\/51034786\/oyad155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:08:32Z","timestamp":1691100512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/e694\/7191800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad155","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,6,7]]}}}